Despite significant advances in the treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As “the dormancy company,” we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal, we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.

At HiberCell, we are focused on developing novel therapeutics to overcome foundational barriers that prevent patients from living longer, cancer-free lives. We recognize cancer as a chronic disease and are focused on developing therapies that address the most common cause of cancer mortality: relapse and metastasis. We believe treatments focused on modulating the foundational barriers that allow treatment-resistant cancer cells to reawaken as relapse and metastasis will meaningfully impact patient outcomes.